Schedule of Summarizes Information About Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding		6,798,529	5,203,529
Weighted Average Exercise Price, Beginning Balance		$ 2.55	$ 2.58
Remaining Contractual Term (Years), Beginning Balance		7 years 3 months 18 days	8 years 1 month 6 days
Intrinsic Value Outstanding, Beginning Balance	[1]	$ 2,558	$ 394
Number of Stock Options, Granted	[2]	2,900,000	1,595,000
Weighted Average Exercise Price, Granted	[2]	$ 4.90	$ 2.13
Number of Stock Option, Exercised		(621,164)
Weighted Average Exercise Price, Exercised		$ 1.58
Number of Stock Option, Forfeited		(357,167)
Weighted Average Exercise Price, Forfeited		$ 2.82
Number of Stock Options Outstanding, Ending Balance		8,720,198	6,798,529	5,203,529
Weighted Average Exercise Price, Ending Balance		$ 3.39	$ 2.55	$ 2.58
Remaining Contractual Term (Years) stock options, Ending Balance		6 years 9 months 18 days	7 years 3 months 18 days
Intrinsic Value Outstanding, Ending Balance	[1]	$ 3,516	$ 2,558	$ 394
Number of Stock Options Vested and exercisable stock options		6,228,106	4,861,433
Weighted Average Exercise Price, Vested and exercisable stock options		$ 2.88	$ 2.88
Remaining Contractual Term (Years), Vested and exercisable stock options		5 years 8 months 12 days	6 years 8 months 12 days
Intrinsic Value Exercisable, Ending Balance	[1]	$ 3,245	$ 1,707
2018 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding		1,399,242	1,403,945
Weighted Average Exercise Price, Beginning Balance		$ 0.61	$ 0.61
Number of Stock Options, Granted	[3]	20,000
Weighted Average Exercise Price, Granted	[3]	$ 9.08
Number of Stock Option, Exercised			(4,703)
Weighted Average Exercise Price, Exercised			$ 1.06
Number of Stock Option, Forfeited
Weighted Average Exercise Price, Forfeited
Number of Stock Options Outstanding, Ending Balance		1,419,242	1,399,242	1,403,945
Weighted Average Exercise Price, Ending Balance		$ 0.60	$ 0.61	$ 0.61
Remaining Contractual Term (Years) stock options, Ending Balance		7 years	8 years	9 years
Number of Stock Options Vested and exercisable stock options		1,337,417	1,085,288
Weighted Average Exercise Price, Vested and exercisable stock options		$ 0.61	$ 0.58
Remaining Contractual Term (Years), Vested and exercisable stock options		7 years	7 years 10 months 24 days

[1] The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of December 31, 2021 and 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.

[2] Stock options granted under the PAVmed Inc. 2014 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.

[3] Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.